For the prevention of nausea and vomiting in patients receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days1
SANCUSO helps prevent chemotherapy-induced nausea and vomiting (CINV) in patients with cancer who are mechanically compromised and/or who may be unable to take or retain oral antiemetics1,2,a,b
This offer is not valid for prescriptions under Medicare (including Medicare Advantage, Part A, B, and D plans), Medicaid, VA, DOD, TRICARE, CHAMPUS, or other federal or state healthcare programs. This offer is not valid for prescriptions in Massachusetts or in any other state that does not permit copay reimbursement consistent with this program. Patients without commercial insurance are not eligible for this program. Unless otherwise indicated on the submission form, SANCUSO will be dispensed through select pharmacies in the ASPN network. Kyowa Kirin, Inc., reserves the right to cancel or modify the program at any time. Offer expires December 31, 2020.
You may have patients with CINV who are ready for SANCUSO. Now you can receive updates about SANCUSO and learn about new resources as they become available.Stay informed
SANCUSO® (granisetron transdermal system) is indicated for the prevention of nausea and vomiting in patients receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days duration.
SANCUSO is contraindicated in patients with known hypersensitivity to granisetron or to any of the components of the patch.
Warnings and Precautions
The most common adverse reaction in patients receiving SANCUSO is constipation (5.4%).